About Manchester Pharma
Manchester Pharma is a Healthcare company based in Fort Collins (United States) founded in 2008, and was acquired by Retrophin in February 2014. Therapeutic modalities for ultra-rare diseases are developed and commercialized. Its focus areas include Life Sciences, Rare Diseases, Drugs and GI. Its competitors include Phathom Pharmaceuticals, Lumena Pharma and Ellodi Pharmaceuticals; 2 of its 3 listed competitors have raised funding.
Company details
Manchester Pharmaceuticals was established in 2008 in Fort Collins, United States, as a specialty pharmaceutical firm. Focus is placed on identifying, developing, and commercializing treatments for ultra-rare diseases. Two FDA-approved products are marketed: Chenodal, a synthetic bile acid for gallstones in high-risk patients, and Vecamyl, tablets for managing severe essential hypertension. Acquisition by Retrophin occurred in February 2014.
- Headquarters Fort Collins, United States
- Stage Acquired
- SectorsHealthcare
- Website manchesterpharma.com
- Social LinkedIn
- Acquired by Retrophin (Feb 2014)
Investors in Manchester Pharma
Manchester Pharma has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Retrophin.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Drugs are developed for debilitating and life-threatening diseases. | 2011 | retrophin.com | San Diego, United States |
Investor details for Manchester Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Manchester Pharma
2 dated milestones of Manchester Pharma across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Manchester Pharma is founded.
- Exit Acquired by Retrophin.
Competitors of Manchester Pharma
Manchester Pharma has 3 listed competitors in our database, 2 of them funded. They include Phathom Pharmaceuticals, Lumena Pharma and Ellodi Pharmaceuticals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| phathompharma.com | 2019 | Menlo Park, United States | $90M | 113 | Therapies for gastrointestinal diseases are developed by Phathom Pharmaceuticals. | |
| lumenapharma.com | 2011 | San Diego, United States | $71.05M | 11 | Passionately pursuing better treatments for adults and children with rare liver diseases. | |
| ellodipharma.com | 2020 | Ewing Township, United States | Therapeutics for Eosinophilic Esophagitis are developed by Ellodi Pharmaceuticals. |
Detailed competitors of Manchester Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as Manchester Pharma (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Manchester Pharma
Manchester Pharma was founded in 2008.
Manchester Pharma is headquartered in Fort Collins, United States. It is registered at Fort Collins, Colorado, United States.
Manchester Pharmaceuticals was established in 2008 in Fort Collins, United States, as a specialty pharmaceutical firm. Focus is placed on identifying, developing, and commercializing treatments for ultra-rare diseases. Two FDA-approved products are marketed: Chenodal, a synthetic bile acid for gallstones in high-risk patients, and Vecamyl, tablets for managing severe essential hypertension. Acquisition by Retrophin occurred in February 2014.
Manchester Pharma's top competitors include Phathom Pharmaceuticals, Lumena Pharma and Ellodi Pharmaceuticals.
Manchester Pharma has 1 investor. Key investors include Retrophin.
Yes. Manchester Pharma was acquired by Retrophin in February 2014.
